Recent Advances in Multiple Myeloma: Highlights from the IMS 2022 Meeting and Beyond - Episode 8

Transplant-Ineligible Multiple Myeloma: The ENDURANCE Study

, , , ,

Andrew Cowan, MD, presents the results of the ENDURANCE study comparing two triplet regimens in transplant-ineligible MM.

EP. 1: Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM
EP. 2: Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM
EP. 3: Determining the Right Patients with NDMM for Autologous Stem Cell Transplant
EP. 4: Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM
EP. 5: Treating Patients with High-Risk NDMM
EP. 6: Factors to Consider for Frontline Treatment of Transplant-Ineligible MM
EP. 7: Transplant-Ineligible Multiple Myeloma: The MAIA and SWOG 0777 Trials
Now Viewing
EP. 8: Transplant-Ineligible Multiple Myeloma: The ENDURANCE Study
EP. 9: Role of Triplet Therapy in Frail Patients with Transplant-Ineligible NDMM
EP. 10: Maintenance Therapy in Transplant-Ineligible NDMM
EP. 11: Available Treatment Options for Relapsed/Refractory Multiple Myeloma
EP. 12: Bispecific Antibodies in the Treatment of R/R MM
EP. 13: CAR-T Therapy in R/R MM Treatment
EP. 14: Choosing a Bispecific Antibody for Treatment of R/R MM After Prior BCMA Therapy
EP. 15: Sequencing Therapies in Patients with R/R MM
EP. 16: Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022
EP. 17: Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

Related Content:

Recent Advances in Multiple Myeloma: Highlights from the IMS 2022 Meeting and BeyondMultiple MyelomaAround the Practice
Defining Frail Patients in Multiple Myeloma
Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM
Treating High-Risk Transplant-Ineligible Newly Diagnosed Multiple Myeloma